| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
Multikinase inhibitor sorafenib is reported to have obtained a better effect than conventional chemotherapy for hepatocellular carcinoma. The influence and function of sorafenib on tumor invasion or metastasis is unknown. In this study, we aimed to analyze the mechanism of sorafenib on hepatocellular carcinoma (HCC) extension including tumor growth, invasion and metastasis and establish predictive model of sorafenib efficacy. Sorafenib inhibited the proliferation of HCC cell KYN2 more than Li7. Sorafenib also induced apoptosis on KYN2 not Li7. Sorafenib reduced the phosphorylation level of LYN on KYN2, but not on Li7. Microarray resulted the signal of LYN, FGFR4 of KYN2 were more than Li7. The difference expression of these tyrosinkinase molecular could be useful to find candidate biomarkers for prediction of sorafenib response.
|
